Episode Details

AI is revolutionizing drug discovery with a new method called CGFlow, developed by scientists at Simon Fraser University. This breakthrough allows AI to design molecules that are not only theoretically effective but also physically buildable in real labs — a major hurdle in traditional drug development. Already being tested for autoimmune diseases like arthritis and Crohn’s, and eyed for early-stage cancer treatments, CGFlow promises to slash the 10-year, multi-billion-dollar timeline for bringing new drugs to patients. With researchers now expanding the tech in the U.K. and other companies exploring its potential, this innovation could dramatically accelerate treatments for a wide range of diseases — making life-saving therapies reach patients faster than ever before.

Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/02023622af200f72